Article
Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study.
The Journal of international medical research - 1 Aug 2020
Jiang Ye, Chen Wenli, Yu Weiguang, Shi Ning, Han Guowei, Mao Shuai, Zhang Xinlei, Chen Meiji
Abstract excerpt
OBJECTIVE: To evaluate survival following afatinib (AF) and erlotinib (ER) treatment in advanced del19 lung adenocarcinoma (AD19LA) with asymptomatic brain metastasis (ABM) after pemetrexed-cisplatin chemotherapy (PCC). METHODS: Data were retrospectively analysed from individuals with AD19LA and ABM after PCC who received AF or ER for 2 years or until intolerable adverse events (AEs), withdrawal, or death. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.